More than one in three people will develop some form of cancer during their lifetime. In the UK, the four most common types of cancer are: breast cancer, lung cancer, prostate cancer and bowel cancer.
Lung cancer killed 1.71million people worldwide in 2016 as the most deadly form of cancer and the third most common overall. Lung cancer survival is mostly determined by the stage at which it is caught, with later-stage diagnosis having poorer survival rates. When found at its earliest stage, more than a third of people with lung cancer will survive the disease for five years or more, compared with around five in 100 of people when discovered at a later stage. This is why effective diagnosis is so important in surviving lung cancer given the rates of survival have not shown much improvement in the last 40 years in the UK.
With symptomatic evidence of cancer affecting over two-thirds of the nation, a remarkable proportion of the population have not yet sought treatment, often causing a huge drop in the survival rates of Britain’s most serious illness, for which, early detection is critical for survival. Whilst innovation in treatment is thought of as the holy grail for beating cancer, alongside this, early detection and accurate diagnosis is a paramount catalyst for stemming cancer before it spreads.
ANCON’s mission is to deliver an innovative, non-invasive technology that can detect a full range of diseases in their earliest stages. Breath analysis is the “Holy Grail” of medical diagnosis technology, providing a simple, inexpensive way to identify minute traces of molecular biomarkers within a point-of-care situation.
Ancon Medical has developed a revolutionary technology called Nanoparticle Biomarker Tagging that gives medical professionals the capability to detect deadly diseases in a patient’s breath.
No matter what the disease, early diagnosis gives medical personnel more opportunities fortreatment. Nanoparticle Biomarker Tagging (NBT) technology offers powerful capabilities to screen for a wide range of diseases with unprecedented sensitivity.
Leading medical technology firm – ANCON Medical – presents nationally representative insight into the state of the UK’s undiagnosed health conditions.